enlicitide decanoate + semaglutide

**Enlicitide decanoate + semaglutide** is an experimental fixed-dose oral combination of two separate pharmaceutical agents: enlicitide decanoate, a macrocyclic peptide and potent, first-in-class oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), and semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist. Enlicitide decanoate is under late-stage clinical investigation for the treatment of hyperlipidemia, heterozygous familial hypercholesterolemia, and cardiovascular risk reduction, showing strong reductions in LDL cholesterol comparable to injectable antibody PCSK9 inhibitors[3][5][7]. Semaglutide is an established GLP-1 agonist with proven efficacy in lowering blood sugar and body weight in type 2 diabetes, obesity, and cardiovascular risk[2][4][6]. The combination aims to address comorbid dyslipidemia and metabolic disease common in at-risk patient populations. Both drugs can be administered orally as tablets[1].